Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the <scp>CLEAR</scp> study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Published:2022-12 Issue:6 Volume:12 Page:6902-6912
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Eto Masatoshi¹^ORCID,Takagi Toshio²,Kimura Go³^ORCID,Fukasawa Satoshi⁴,Tamada Satoshi⁵,Miura Yuji⁶,Oya Mototsugu⁷,Sassa Naoto⁸,Anai Satoshi⁹,Nozawa Masahiro¹⁰,Sakai Hideki¹¹,Perini Rodolfo¹²,Yusa Wataru¹³,Ikezawa Hiroki¹⁴,Narita Tomoyuki¹⁵,Tomita Yoshihiko¹⁶

Affiliation:

1. Department of Urology Kyushu University Hospital Fukuoka Japan

2. Department of Urology Tokyo Women's Medical University Hospital Tokyo Japan

3. Department of Urology Nippon Medical School Hospital Tokyo Japan

4. Prostate Center and Division of Urology Chiba Cancer Center Chiba Japan

5. Department of Urology Bell‐land General Hospital Osaka Japan

6. Department of Medical Oncology Toranomon Hospital Tokyo Japan

7. Department of Urology Keio University Hospital Tokyo Japan

8. Department of Urology Aichi Medical University Aichi Japan

9. Department of Urology Nara Medical University Nara Japan

10. Department of Urology Kindai University Hospital Osaka Japan

11. Department of Urology Nagasaki University Hospital Nagasaki Japan

12. Merck & Co., Inc. Rahway New Jersey USA

13. Japan and Asia Clinical Development Department Oncology Business Group, Eisai Co., Ltd. Tokyo Japan

14. Clinical Data Science Department, Medicine Development Center Eisai Co., Ltd. Tokyo Japan

15. Lenvima Alliance Management Eisai Co., Ltd. Tokyo Japan

16. Department of Urology, Department of Molecular Oncology Niigata University Graduate School of Medicine Niigata Japan

Funder

Eisai Incorporated

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5483

Reference24 articles.

1. Epidemiology of Renal Cell Carcinoma

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

3. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of the efficacy and safety of lenvatinib in various solid tumors;Immunopharmacology and Immunotoxicology;2024-04-23

2. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer;International Journal of Urology;2024-02-06

3. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer;Journal of Gynecologic Oncology;2024

4. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population;Expert Review of Anticancer Therapy;2023-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3